Levetiracetam Vir (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. By influencing this protein, the drug stabilizes neuronal activity and reduces the likelihood of excessive firing that leads to seizures, without directly altering ion channels or GABA activity.

The specific dosage of Levetiracetam Vir is determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and response to therapy. Patients should follow the dose prescribed by their healthcare professional and not adjust it independently.

The safety of Levetiracetam in pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks, and women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which can provide effective seizure control with a relatively favorable interaction profile compared with enzyme‑inducing agents like carbamazepine or phenytoin. Its once‑ or twice‑daily dosing and limited hepatic metabolism make it a convenient option for many patients.

Levetiracetam Vir should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or extreme temperatures.

Levetiracetam Vir is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with water; they are not intended for crushing, chewing, or splitting unless specifically advised by a healthcare professional.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, suicidal thoughts or behaviors, major depressive episodes, and rare blood disorders. Patients should promptly report any rash, mood changes, or unusual symptoms to their healthcare provider.

Levetiracetam Vir is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking medications that significantly reduce levetiracetam levels without appropriate monitoring.